To include your compound in the COVID-19 Resource Center, submit it here.

Kuros regains Baxter products, reports data

Kuros Biosurgery AG (Zurich, Switzerland) on Tuesday regained rights to three musculoskeletal repair candidates from partner Baxter International Inc. (NYSE:BAX) and reported Phase IIb

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE